2018
Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity
Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity. Cancer Research 2018, 78: canres.0171.2018. PMID: 29764863, DOI: 10.1158/0008-5472.can-18-0171.Peer-Reviewed Original ResearchConceptsT cellsT cell antitumor immunityTumor-specific T cellsTumor cellsEffective immunotherapeutic agentFavorable safety profileResponder T cellsDendritic cell differentiationTumor-challenged miceImmunogenic cell deathSelective antitumor effectApoptotic tumor cellsPotential therapeutic applicabilityProcessing/presentationAntimelanoma immunityHealthy DCsImmunogenic malignanciesAntitumor immunityCellular vaccinesImmunotherapeutic effectsAdditional malignanciesImmunotherapeutic agentsSafety profileCancer immunotherapyTumor antigens
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1 therapyCutaneous adverse effectsPD-L1 therapyCell death 1Concurrent medicationsDeath-1Adverse effectsClinical morphologyAnti-PD-1/PD-L1 treatmentAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesAnti-programmed cell death 1Non-small cell lung cancerDeath ligand 1 (PD-L1) immunotherapyPD-L1 antibody therapyCell death ligand 1Yale-New Haven HospitalMucocutaneous adverse effectsPD-L1 treatmentTreatment of rashTertiary care hospitalDeath ligand 1Lichenoid drug eruptionCell lung cancerSkin biopsy specimensRecent US Food
2004
Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma.
Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. Advances In Dermatology 2004, 20: 217-35. PMID: 15544202.Peer-Reviewed Original Research
2003
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.Peer-Reviewed Original ResearchConceptsLow side effect profileSide effect profilePotential novel strategyMechanism of actionImmunosuppressive medicationsExtracorporeal photochemotherapyEffect profileTransplant rejectionTreatment of cancerClinical recordsRole of ECPClinical studiesT cellsTreatment considerationsModern therapeuticsTreatmentNovel strategyGVHDMedicationsAutoimmunityCTCLMalignancyECPTherapyCancer
2002
Transimmunization and the evolution of extracorporeal photochemotherapy
Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion And Apheresis Science 2002, 26: 181-190. PMID: 12126204, DOI: 10.1016/s1473-0502(02)00011-3.Peer-Reviewed Original ResearchMeSH KeywordsDendritic CellsGraft vs Host DiseaseHumansImmunotherapyNeoplasmsPhotopheresisT-Lymphocytes, CytotoxicConceptsDC/T cell interactionExtracorporeal photopheresisT cell responsesT cell interactionsT cell receptorPotent T cell responsesSpecific T cell responsesCutaneous T-cell lymphomaT cell-mediated diseaseDendritic cell therapyT cell reactionsT-cell lymphomaOrgan transplant rejectionT-cell malignanciesExtracorporeal photochemotherapySelective immunotherapyTransplant rejectionImmune effectsImmune responsePatients' leukocytesCell malignanciesEffective antigenCell therapyFirst FDACancer cellsTransimmunization, a novel approach for tumor immunotherapy
Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion And Apheresis Science 2002, 26: 205-216. PMID: 12126207, DOI: 10.1016/s1473-0502(02)00014-9.Peer-Reviewed Original ResearchMeSH KeywordsDendritic CellsHumansImmunotherapyLeukapheresisLymphoma, T-Cell, CutaneousNeoplasmsPhotopheresisConceptsCutaneous T-cell lymphomaImmune responseTumor antigensPotent antigen presenting cellsAnti-tumor immune responseExtracorporeal photopheresis (ECP) treatmentDendritic cell immunotherapyT-cell lymphomaAntigen presenting cellsPeripheral blood monocytesApoptotic tumor cellsApoptotic CTCL cellsPhotopheresis treatmentRejection episodesHost diseaseOvernight incubation periodTumor epitopesImmature DCsCell immunotherapyTumor immunotherapyAutoimmune diseasesDC differentiationInflammatory cytokinesPresenting cellsCell lymphoma